The Health Press - Zambia, Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia.
Michael Chilufya Sata School of Medicine, Copperbelt University, Ndola, Zambia.
BMC Infect Dis. 2020 Feb 3;20(1):101. doi: 10.1186/s12879-020-4806-5.
Rubella is highly under reported in Zambia as in most sub-Saharan countries despite being a disease of major public health concern especially among women of childbearing age. In September 2016, Zambia introduced a combined measles-rubella vaccine in children 0-14 years. In this study, we estimated the proportion positive for acute rubella among suspected but negative measles cases between 2005 and 2016 and determined its correlates for monitoring rubella epidemiology post-rubella vaccine introduction.
In a retrospective study, 4497 measles IgM negative serum samples from 5686 clinically suspected measles cases were examined for rubella IgM antibodies using the Siemens, Enzygnost® ELISA kit at the national measles laboratory. Data on demographics, year and month of onset were extracted from the surveillance data. Multivariate logistic regression analysis using backward variable selection was conducted to determine independent predictors for acute rubella. The magnitude of association was estimated using adjusted odds ratio with a 95% confidence interval.
Overall, a proportion of 29.2% (1313/4497) affecting mostly those between 5 and 24 years was determined. Only age, province, month and year were independently associated with acute rubella. The regional proportions varied from 21.8-37.3% peaking in the month of October. Persons in the age group 10-14 years (Adjusted Odds Ratio [AOR] = 2.43; 95% CI [2.01-2.95]) were more likely while those aged < 1 year less likely (AOR = 0.31; 95% CI [021-0.48]) to have acute rubella compared to those aged 25 years or older. Persons in 2010 were less likely (AOR = 0.12; CI [0.05, 0.28]) to have acute rubella compared to those in 2016. While acute rubella was more likely to occur between July and November compared to December, it was less likely to occur between February and May.
Rubella virus was circulating in Zambia between 2005 and 2016 affecting mostly persons in the age group 5-24 years peaking in the hot dry season month of October. Although vaccination against rubella has been launched, these baseline data are important to provide a reference point when determining the impact of the vaccination program implemented.
尽管风疹是撒哈拉以南非洲国家,尤其是育龄妇女关注的主要公共卫生问题之一,但在赞比亚,风疹的报告率非常低,就像在大多数撒哈拉以南非洲国家一样。2016 年 9 月,赞比亚在 0-14 岁儿童中引入了麻疹-风疹联合疫苗。在这项研究中,我们估算了 2005 年至 2016 年间疑似麻疹但麻疹 IgM 阴性病例中急性风疹的阳性比例,并确定了监测风疹疫苗引入后风疹流行病学的相关因素。
在一项回顾性研究中,在国家麻疹实验室使用西门子 Enzygnost® ELISA 试剂盒检测了来自 5686 例临床疑似麻疹病例的 4497 份麻疹 IgM 阴性血清样本,以检测风疹 IgM 抗体。从监测数据中提取了人口统计学、发病年份和月份的数据。采用向后变量选择的多变量逻辑回归分析确定急性风疹的独立预测因素。使用调整后的优势比及其 95%置信区间来估计关联程度。
总体而言,确定了 29.2%(1313/4497)的比例,主要影响 5 至 24 岁的人群。只有年龄、省份、月份和年份与急性风疹独立相关。各地区的比例从 21.8%到 37.3%不等,10 月达到高峰。10-14 岁年龄组的人更有可能(调整后的优势比[OR] = 2.43;95%置信区间[CI] = 2.01-2.95),而年龄<1 岁的人不太可能(OR = 0.31;95%CI [0.21-0.48])发生急性风疹与 25 岁或以上的人相比。与 2016 年相比,2010 年发生急性风疹的可能性更小(OR = 0.12;CI [0.05,0.28])。与 12 月相比,7 月至 11 月急性风疹更常见,而 2 月至 5 月则较少。
2005 年至 2016 年间,风疹病毒在赞比亚流行,主要影响 5-24 岁人群,10 月的旱热季节达到高峰。尽管已推出风疹疫苗,但这些基线数据对于确定实施疫苗接种计划的影响非常重要。